Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DO-IT: DOAC Intravenous Thrombolysis Trial
NCT06571149Phase 4Recruiting
- Sponsor
- Insel Gruppe
- Start
- Mar 2025
- Primary completion
- Jan 2029
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 12
01
Overview
A Phase 4 trial of tenecteplase, tissue-plasminogen activator in ischemic stroke, sponsored by Insel Gruppe. Started Mar 2025; status: recruiting.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06571149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571149.